Natural History Studies for Rare Diseases

Автор: U.S. Food and Drug Administration

Загружено: 2016-02-29

Просмотров: 74160

Описание: The purpose of the video is to inform patients, patient advocates, caregivers, scientists and others who have an interest in rare diseases about the importance of natural history studies. The Food and Drug Administration’s (FDA) Office of Orphan Products Development is introducing a new grants program to support natural history studies This video is a moderated discussion between FDA physicians, a patient, a caregiver and the chair of the scientific advisory board for a patient advocacy group.

Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...

Natural History Studies for Rare Diseases

Доступные форматы для скачивания:

Скачать видео

Информация по загрузке:

Скачать аудио

Похожие видео

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

Medical Device Quality Management System Regulation Risk Management

Medical Device Quality Management System Regulation Risk Management

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

Medical Device Quality Management System Regulation Design and Development

Medical Device Quality Management System Regulation Design and Development

Public Meeting: Reauthorization of the Biosimilar User Fee Act

Public Meeting: Reauthorization of the Biosimilar User Fee Act

Initiating the Removal of the “Black Box Warning” on Hormone Replacement Therapy

Initiating the Removal of the “Black Box Warning” on Hormone Replacement Therapy

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

2025 FDA Achievements

2025 FDA Achievements

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA-USP-AAM | D1S4 – Q&A Discussion Panel

FDA-USP-AAM | D1S4 – Q&A Discussion Panel

FDA Celebrates 120 Years

FDA Celebrates 120 Years

Tobacco Products Scientific Advisory Committee Meeting, October 7, 2025

Tobacco Products Scientific Advisory Committee Meeting, October 7, 2025

January 22, 2026: Tobacco Products Scientific Advisory Committee Meeting

January 22, 2026: Tobacco Products Scientific Advisory Committee Meeting